Show simple item record

 

Plain-language commentary: 2-year findings from the FIREFLEYE next study looking at how well aflibercept injected into affected eyes in babies with retinopathy of prematurity works and how safe it is compared with laser treatment

dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorStahl, Andreas
dc.contributor.authorNakanishi, Hidehiko
dc.contributor.authorLepore, Domenico
dc.contributor.authorWu, Wei-Chi
dc.contributor.authorAzuma, Noriyuki
dc.contributor.authorJacas, Carlos
dc.date.accessioned2025-10-17T12:43:45Z
dc.date.available2025-10-17T12:43:45Z
dc.date.issued2025-08
dc.identifier.citationStahl A, Nakanishi H, Lepore D, Wu WC, Azuma N, Jacas C, et al. Plain-language commentary: 2-year findings from the FIREFLEYE next study looking at how well aflibercept injected into affected eyes in babies with retinopathy of prematurity works and how safe it is compared with laser treatment. Ther Adv Ophthalmol. 2025 Aug;17:25158414251321730.
dc.identifier.issn2515-8414
dc.identifier.urihttp://hdl.handle.net/11351/13880
dc.descriptionInfants; Intravitreal aflibercept; Retinopathy of prematurity
dc.language.isoeng
dc.publisherSAGE Publications
dc.relation.ispartofseriesTherapeutic Advances in Ophthalmology;17
dc.rightsAttribution-NonCommercial 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.sourceScientia
dc.subjectAvaluació de resultats (Assistència sanitària)
dc.subjectInfants prematurs
dc.subjectRetina - Malalties - Tractament
dc.subjectInjeccions
dc.subjectRetina - Malalties - Cirurgia per làser
dc.subjectAngiogènesi - Inhibidors - Ús terapèutic
dc.subject.meshTreatment Outcome
dc.subject.meshRetinopathy of Prematurity
dc.subject.mesh/therapy
dc.subject.meshIntravitreal Injections
dc.subject.meshLaser Therapy
dc.subject.meshAngiogenesis Inhibitors
dc.titlePlain-language commentary: 2-year findings from the FIREFLEYE next study looking at how well aflibercept injected into affected eyes in babies with retinopathy of prematurity works and how safe it is compared with laser treatment
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1177/25158414251321730
dc.subject.decsresultado del tratamiento
dc.subject.decsretinopatía del prematuro
dc.subject.decs/terapia
dc.subject.decsinyecciones intravítreas
dc.subject.decstratamiento con láser
dc.subject.decsinhibidores de la angiogénesis
dc.relation.publishversionhttps://doi.org/10.1177/25158414251321730
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Stahl A] Department of Ophthalmology, University Medicine Greifswald, Ferdinand Sauerbruch Straße, Greifswald, Germany. [Nakanishi H] Division of Neonatal Intensive Care Medicine, Department of Advanced Medicine, Research and Development Center for New Medical Frontiers, Kitasato University School of Medicine, Sagamihara, Japan. [Lepore D] Department of Geriatrics and Neuroscience, Catholic University of the Sacred Heart, A. Gemelli Foundation Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy. [Wu WC] Department of Ophthalmology, Linkou Chang Gung Memorial Hospital and College of Medicine, Chang Gung University, Taoyuan City, Taiwan. [Azuma N] Department of Developmental and Regenerative Biology, Medical Research Institute, Institute of Science Tokyo, Tokyo, Japan. [Jacas C] Servei de Psiquiatria, Vall d’Hebron Hospital Universitari, Barcelona, Spain
dc.identifier.pmid40342575
dc.identifier.wos001484255500001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail
Name:
plain-language-commentary-2-ye ...
Size:
118.9Kb
Format:
PDF
Description:
Plain-language commentary: 2-year ...
View

This item appears in the following Collection(s)

Show simple item record